Ameriprise
NRIX icon

Ameriprise’s Nurix Therapeutics NRIX Stock Holding History

Ameriprise’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,825
Closed -$958K – 4209
2026
Q1 		$958K Sell
61,825
-62,924
-50% -$1.04M ﹤0.01% 3316
2025
Q4 		$2.37M Buy
124,749
+20,116
+19% +$289K ﹤0.01% 2913
2025
Q3 		$967K Buy
104,633
+62,447
+148% +$648K ﹤0.01% 3382
2025
Q2 		$480K Buy
42,186
+11,500
+37% +$124K ﹤0.01% 3543
2025
Q1 		$365K Sell
30,686
-1,466
-5% -$24.5K ﹤0.01% 3613
2024
Q4 		$606K Buy
32,152
+16,921
+111% +$388K ﹤0.01% 3450
2024
Q3 		$342K Sell
15,231
-31,573
-67% -$715K ﹤0.01% 3604
2024
Q2 		$977K Sell
46,804
-59,060
-56% -$920K ﹤0.01% 3169
2024
Q1 		$1.56M Sell
105,864
-4,848
-4% -$52.1K ﹤0.01% 2986
2023
Q4 		$1.14M Buy
110,712
+50,394
+84% +$345K ﹤0.01% 3132
2023
Q3 		$474K Buy
+60,318
New +$551K ﹤0.01% 3433
2023
Q2 		– Sell
-40,649
Closed -$361K – 3975
2023
Q1 		$361K Buy
40,649
+17,949
+79% +$187K ﹤0.01% 3546
2022
Q4 		$249K Buy
+22,700
New +$274K ﹤0.01% 3654
2021
Q3 		– Sell
-224,686
Closed -$5.96M – 3916
2021
Q2 		$5.96M Buy
224,686
+5,065
+2% +$149K ﹤0.01% 2329
2021
Q1 		$6.83M Buy
219,621
+90,821
+71% +$3.44M ﹤0.01% 2183
2020
Q4 		$4.24M Sell
128,800
-126,448
-50% -$4.19M ﹤0.01% 2383
2020
Q3 		$8.91M Buy
+255,248
New +$6.43M ﹤0.01% 1637

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's NRIX Position: Q2 2026 in Review

Ameriprise sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 61,825 shares — an estimated $958K sold.

Ameriprise first reported a position in NRIX in Q3 2020 and held it in 17 quarters. The position peaked at $8.91M in Q3 2020. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Ameriprise reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameriprise sold 61,825 Nurix Therapeutics shares in Q2 2026, an estimated $958K.
  • Ameriprise first reported a position in Nurix Therapeutics in Q3 2020 and held it in 17 quarters.
  • Ameriprise's Nurix Therapeutics position peaked at $8.91M in Q3 2020.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.